
A row has broken out between Vertex Pharmaceuticals (VRTX) and Canadian officials over access to its cystic fibrosis medicines, the latest instance in which the drug maker has locked horns with a government.
The drug maker maintained that five separate offers were made over the past several years to the pan-Canadian Pricing Alliance, which conducts joint negotiations on behalf of the provincial, territorial, and federal governments in the country, although provinces make reimbursement decisions. In response to questions, a Vertex spokeswoman claimed the company never received any feedback or opportunity to hold formal talks over three cystic fibrosis treatments that are approved for use in Canada.